OncoMatch/Clinical Trials/NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Is NCT03630991 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Edetate Calcium Disodium and Succimer for acute myeloid leukemia.
Treatment: Edetate Calcium Disodium · Succimer — This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Performance status
ECOG/LANSKY/KARNOFSKY 0–3
ECOG performance status of =< 3 or Lansky or Karnofsky ≥ 30 at study entry; patients who are unable to walk, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Lab requirements
Kidney function
Serum creatinine <= 1.5 mg/dL
Liver function
Total Bilirubin <= 2.0 x ULN, unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) <= 2.0 x ULN
Laboratory test results within these ranges (unless due to leukemia or other hematologic malignancy): Serum creatinine <= 1.5 mg/dL; Total Bilirubin <= 2.0 x ULN, unless the patient has Gilbert's; AST (SGOT) and/or ALT (SGPT) <= 2.0 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify